<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Increased cardiovascular risk in <z:mp ids='MP_0002055'>diabetes</z:mp> cannot be attributed to the higher prevalence of classic risk factors </plain></SENT>
<SENT sid="1" pm="."><plain>IMPORTANCE OF POSTPRANDIAL <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">HYPERGLYCEMIA</z:e>: Most of the <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> have shown to be directly related to the degree of postprandial glycemia (<z:chebi fb="73" ids="53262">PPG</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="73" ids="53262">PPG</z:chebi> should be recognized as a marker for the increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>ASSESSMENT OF TARGETS FOR GLYCEMIA CONTROL: Two important methods available-self-monitoring of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (SMBG) reveals immediate hour-to-hour blood <z:chebi fb="105" ids="17234">glucose</z:chebi>, while long-term glycemia is assessed by HbA1c </plain></SENT>
<SENT sid="4" pm="."><plain>Reducing <z:chebi fb="73" ids="53262">PPG</z:chebi> and glycemia excursions is as important as lowering fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> and HbA1c levels </plain></SENT>
<SENT sid="5" pm="."><plain>EFFECTIVENESS OF SMBG: SMBG plays a key role in <z:mp ids='MP_0002055'>diabetes</z:mp> care, and has proven to be effective for insulin treated type 2 diabetic patients </plain></SENT>
<SENT sid="6" pm="."><plain>Debate continues on the effectiveness of SMBG in non-insulin treated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Whether non-insulin treated type 2 diabetic patients benefit from SMBG, a large-scale randomized controlled trial with the follow-up period to investigate long-term effects should be carried out </plain></SENT>
<SENT sid="8" pm="."><plain>A general recommendation is that insulin treated patients perform SMBG at least three times per day </plain></SENT>
<SENT sid="9" pm="."><plain>SMBG frequency for non-insulin users should be individualized to treatment regimen and level of control </plain></SENT>
</text></document>